血浆纤溶酶原激活物抑制剂(PAI)-1是纤溶系统的主要调控因子。近年研究发现,PAI- 1的升高是代谢综合征的一个核心特征,与肥胖、胰岛素抵抗、2型糖尿病、心血管疾病、脂代谢紊乱和高血压等密切相关,甚至可能影响内脏脂肪的蓄积。因此,对PAI—1的直接抑制不仅为降低心血管危险因素提供新的治疗策略,也对治疗肥胖、胰岛素抵抗及2型糖尿病等有益。 Plasma plasminogen activator inhibitor (PAI) -1 is the major regulator of the fibrinolytic system. Recent studies have found that elevated PAI-1 is a core feature of the metabolic syndrome and is closely related to obesity, insulin resistance, type 2 diabetes, cardiovascular diseases, disorders of lipid metabolism and hypertension, and may even affect visceral fat accumulation . Therefore, direct inhibition of PAI-1 not only provides a new treatment strategy for reducing cardiovascular risk factors, but also is beneficial for the treatment of obesity, insulin resistance and type 2 diabetes.